Abstract 1837P
Background
Prior data have shown that prostate specific antigen (PSA) ≤ 0.2 ng/dL with androgen deprivation therapy (ADT) is prognostic for OS. We explored whether PSA ≤ 0.2 ng/dL at 4-7 months post randomization is a valid surrogate for OS in men with mHSPC. If so, it could be used to expedite phase 3 clinical trials. This hypothesis was investigated by the STOPCAP M1 Collaboration.
Methods
Individual patient data (IPD) from 13 eligible randomized trials comparing treatment regimens (ADT or docetaxel in the control or research arms in mHSPC) were utilized. We considered PSA measurements collected post randomization and evaluated the surrogacy of PSA ≤ 0.2 ng/dL at 4-7 months at the patient and trial levels. We utilized the proportional hazards model and estimated the hazard ratios (HR) for PSA ≤ 0.2 ng/dL predicting OS. We also fitted weighted linear regression, stratified by trial and treatment arm, and computed R2 to quantify the proportion of variance that was explained by the regressions. We defined a priori clinically relevant surrogacy of R2 value greater than 0.75. Lastly, we computed the surrogate threshold effect (STE), which is the minimum PSA treatment effect necessary to estimate a non-zero effect on OS.
Results
IPD from 5513 pts randomized from 1994-2012 from 13 trials were pooled for a stratified analysis. There were 3324 deaths, of which 70.5% were due to prostate cancer. The median follow-up was 74 months. At 4-7 months, the proportion of patients who had PSA ≤0.2 was 25.8%. At the individual level, PSA ≤0.2 ng/dL was a strong predictor of OS. Median OS in patients who experienced PSA≤0.2 and the results for the surrogacy analysis are presented in the table.
Table: 1837P
PSA<=0.2 ng/dL (n=1425) | PSA>0.2 ng/dL (n=4088) | |
Median OS months (95%CI) | 91.6 (85.1-98.2) | 40.9 (39.3-42.7) |
Hazard Ratio (95% CI) | 2.5 (2.3-2.7) | |
Condition 2 | 0.93 (0.78-0.99) | |
STE | 0.75 |
Conclusions
PSA≤0.2 ng/dL at 4-7 months met the surrogacy criteria and appears to be a valid surrogate endpoint for OS in men with mHSPC treated with ADT as back-bone hormonal therapy. Validation of this endpoint in trials with drugs having other mechanisms of action is planned.
Clinical trial identification
NCT00002651, NCT00216060, NCT00079001, NCT00104715, NCT00268476, NCT00309985, NCT00685646.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Prostate Cancer Foundation UK Prostate Cancer.
Disclosure
S. Halabi: Financial Interests, Personal, Other, Member of DSMB: Sanofi, Aveo Oncology, BMS, Janssen; Financial Interests, Institutional, Funding: ASCO. M.K. Parmar: Financial Interests, Institutional, Full or part-time Employment, Director at MRC Clinical Trials Unit at UCL: Medical Research Council Clinical Trials Unit at UCL; Financial Interests, Institutional, Research Grant: AstraZeneca, Astellas, Janssen, Clovis; Non-Financial Interests, Advisory Role, Euro Ewing Consortium: University College London; Non-Financial Interests, Advisory Role, rEECur: University of Birmingham; Non-Financial Interests, Advisory Role, CompARE Trial: University of Birmingham. M. Hussain: Financial Interests, Personal, Advisory Board: AstraZeneca, Janssen Pharmaceuticals, Merck & Co, Novartis, Pfizer, Bayer, Tempus Health, Convergent; Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Medscape, Merck, MLI Peer View, Research To Practice (RTP), Great Debates and Updates in GU Oncology; Financial Interests, Institutional, Research Funding: Arvinas, AstraZeneca, Bayer, Genentech. I.M. Thompson: Financial Interests, Personal, Coordinating PI, Clinical trial. Relationship has ended: Magforce; Financial Interests, Personal, Steering Committee Member, investigator in clinical trial: AbbVie. M.J. Morris: Financial Interests, Personal, Advisory Board: Oric, Pfizer, Exelixis, Lantheus, AstraZeneca, Amgen, Daiichi Sankyo, Convergent, Clarity Pharmaceuticals, Blue Earth Diagnostics, POINT Biopharma, Telix, Z-alpha; Financial Interests, Personal, Invited Speaker: Progenics, ITM Isotope Technologies; Financial Interests, Personal, Stocks/Shares: Doximity; Financial Interests, Institutional, Coordinating PI: Novartis, Celgen; Financial Interests, Institutional, Local PI: Corcept, Janssen, Astellas; Non-Financial Interests, Advisory Role: Bayer, Janssen Oncology, Novartis; Other, Other, Travel to conference: AstraZeneca; Other, Other, Travel/lodging at conference: APCCC. G. Gravis: Financial Interests, Institutional, Invited Speaker: AAA, Amgen, Astellas, BMS, Janssen, MSD, Pfizer, Ipsen, AstraZeneca alliance Merck Pfizer, Bayer, Eisai; Financial Interests, Institutional, Advisory Board: Alliance Merck-Pfizer, BMS, Janssen, Pfizer, ipsen, Bayer, Eisai; Non-Financial Interests, Principal Investigator: BMS, Ipsen, Merck; Financial Interests, Institutional, Funding: Janssen; Financial Interests, Institutional, Coordinating PI: BMS. D. Dearnaley: Financial Interests, Personal, Advisory Role: Janssen Pharma; Financial Interests, Institutional, Research Grant: Cancer Research UK, National Institute for Health Research (NIHR) Biomedical Research Centre; Financial Interests, Personal, Proprietary Information: ICR. N.D. James: Financial Interests, Personal, Advisory Board, Advice around PARP inhibitors: AstraZeneca; Financial Interests, Personal, Advisory Board, Prostate cancer therapies: Janssen, Clovis, Novartis; Financial Interests, Institutional, Advisory Board, Assisted with submissions regarding licencing for abiraterone: Janssen; Financial Interests, Personal, Advisory Board, Docetaxel: Sanofi; Financial Interests, Institutional, Advisory Board, Providing STAMPEDE trial data to facilitate licence extensions internationally for docetaxel: Sanofi; Financial Interests, Personal, Advisory Board, Bladder cancer therapy: Merck; Financial Interests, Personal, Advisory Board, Advice around novel hormone therapies for prostate cancer: Bayer; Financial Interests, Personal, Invited Speaker, Lecture tour in Brazil August 2022 - speaking on therapy for advanced prostate cancer: Merck Sharp & Dohme (UK) Limited; Financial Interests, Institutional, Coordinating PI, Funding for STAMPEDE trial: Janssen, Astellas; Financial Interests, Institutional, Coordinating PI, Funding for RADIO trial bladder cancer: AstraZeneca. M.E. Buyse: Financial Interests, Personal, Stocks or ownership: IDDI. C. Sweeney: Financial Interests, Personal, Advisory Board, Consultancy: Genentech Roche, Bayer, Astellas, Pfizer, Pfizer, Sanofi, Lilly; Financial Interests, Personal, Other, Consultancy: Janssen; Financial Interests, Personal, Advisory Board: Point, Cellcentric; Financial Interests, Personal, Stocks/Shares: Leuchemix; Financial Interests, Institutional, Research Grant: Bayer, Janssen, Astellas, Pfizer, Dendreon, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1841TiP - Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)
Presenter: Alicia Morgans
Session: Poster session 15
1842TiP - Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)
Presenter: Johann de Bono
Session: Poster session 15
1922P - Immunosarc II master trial: phase II of sunitinib and nivolumab in vascular sarcomas cohort - A GEIS, ISG and UCL study
Presenter: Nadia Hindi Muñiz
Session: Poster session 15
1923P - Combined analysis of phase III ANNOUNCE study and phase II study exploring olaratumab in advanced soft tissue sarcoma
Presenter: Yoichi Naito
Session: Poster session 15
1924P - Targeting microenvironment and cellular immunity in sarcomas with trabectedin combined with metronomic cyclophosphamide: The TARMIC study
Presenter: Cheng-Ming Sun
Session: Poster session 15
1925P - Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma
Presenter: Neal Chawla
Session: Poster session 15
1926P - Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study
Presenter: Javier Martin-Broto
Session: Poster session 15
1927P - Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
Presenter: Axel Le Cesne
Session: Poster session 15
1928P - Differential presentation and outcome of sclerosing epithelioid fibrosarcoma (SEF) vs low grade fibromyxoid sarcoma (LGFMS): The nationwide series of 330 patients in NETSARC since 2010
Presenter: Jean-Yves Blay
Session: Poster session 15
1929P - phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 15